JBLU, SFM, VRNS and more

Check out the companies making headlines in midday trading: JetBlue — The airline soared almost 20% after reporting second-quarter earnings that beat analysts' expectations . The New York City-based carrier posted adjusted earnings of 8 cents per share, excluding one-time items, compared to analysts' estimated loss of 11 cents...

Read more...

Microsoft (MSFT) Q4 earnings report 2024

Microsoft CEO Satya Nadella speaks during the company's Build developer conference in Seattle on May 21, 2024.Jason Redmond | AFP | Getty ImagesMicrosoft is scheduled to report fiscal fourth-quarter earnings after U.S. market close on Tuesday.Here's what analysts polled by LSEG are looking for:Earnings per share: $2.93Revenue: $64.39 billionMicrosoft...

Read more...

StanChart unveils $1.5 billion share buyback, boosts income guidance

Standard Chartered Plc bank branch in Hong KongBloomberg | Bloomberg | Getty ImagesStandard Chartered (StanChart) on Tuesday announced its largest-ever share buyback worth $1.5 billion and lifted its earnings outlook for this year, betting on strong economic growth in its core Asian markets and plans to rein in costs.The...

Read more...

Stocks making the biggest moves premarket: CRWD, MRK, PYPL, JBLU

Check out the companies making headlines in premarket trading. CrowdStrike — Shares slipped 5% after CNBC reported that stated Delta Airlines has retained legal counsel to pursue damages from both CrowdStrike and Microsoft following after a software update led to mass flight interruptions in July. Woodward — The aerospace...

Read more...

Novo Nordisk GLP-1 liraglutide may slow Alzheimer’s progression

A box of the drug Victoza, made by Novo Nordisk Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020.George Frey | ReutersAn older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer's disease by protecting patients'...

Read more...

Pfizer (PFE) earnings Q2 2024

Kena Betancur | Corbis News | Getty ImagesPfizer on Thursday reported second-quarter revenue and adjusted earnings that blew past expectations and raised its full-year outlook, benefiting from its broad cost-cutting program, better-than-expected sales of its Covid antiviral pill Paxlovid and strong non-Covid product sales.Pfizer now expects to book adjusted earnings of...

Read more...